This Project Grant award for $793,828 from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), supports research to develop lipid nanoparticle therapies for delivering inhibitory RNA cargos to treat contractile dysfunction in heart failure. The proposed research aims to characterize the effects of different inhibitory RNA payloads delivered via cardiotropic lipid nanoparticles (CLNPs), and determine if short-term VASH2 inhibition or sustained VASH1 inhibition can improve cardiac function in animal models of acute myocardial infarction and heart failure with preserved ejection fraction, respectively. This work seeks to establish the therapeutic potential of modulating microtubule network remodeling for treating cardiac contractile disorders. The research will be conducted by the Trustees of the University of Pennsylvania, through their Clinical Practices division, and is expected to be completed by April 2028.
Generated 2/25/25, 5:07 AM